Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection

Elisabetta Degasperi, Flavio Caprioli, Omar El Sherif, David Back, Massimo Colombo, Alessio Aghemo

Research output: Contribution to journalReview articlepeer-review


Introduction: Inflammatory bowel diseases (IBD) require long-term administration of immunomodulatory treatments to maintain disease remission. Due to the high worldwide prevalence of hepatitis B (HBV) or C (HCV) virus infections, presence of concurrent hepatitis can be a relevant clinical issue to manage when treating IBD. Areas covered: The paper summarizes epidemiological data about IBD and HBV/HCV infection and reviews current knowledge about the natural history of HBV and HCV in the IBD setting, concentrating on risk of hepatitis reactivation during immunosuppressive treatment. Most updated recommendations for management of HBV and HCV infections in IBD patients are discussed. Expert commentary: The development of new drugs for IBD with different molecular targets and the availability of potent and efficacious antiviral drugs for HBV and HCV will simplify management of hepatitis infection in IBD patients in the near future.

Original languageEnglish
Pages (from-to)1373-1383
Number of pages11
JournalExpert Review of Gastroenterology and Hepatology
Issue number12
Publication statusPublished - Dec 1 2016


  • Anti-TNF
  • HBV
  • HCV
  • immunosuppressive treatment
  • inflammatory bowel diseases
  • viral hepatitis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection'. Together they form a unique fingerprint.

Cite this